Quality of life should be the primary outcome for disease-modifying therapy trials in MS: Commentary

Quality of life should be the primary outcome for disease-modifying therapy trials in MS: Commentary

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Multiple sclerosis 2023-08, Vol.29 (9), p.1068-1069
1. Verfasser: Giovannoni, Gavin
Format: Artikel
Sprache:eng
Schlagworte:
Humans
Immunosuppressive Agents
Multiple Sclerosis - drug therapy
Multiple Sclerosis, Relapsing-Remitting - drug therapy
Quality of Life
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1069
container_issue 9
container_start_page 1068
container_title Multiple sclerosis
container_volume 29
creator Giovannoni, Gavin
description
doi_str_mv 10.1177/13524585231182702
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2841881066</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1177_13524585231182702</sage_id><sourcerecordid>2848139897</sourcerecordid><originalsourceid>FETCH-LOGICAL-c320t-93411c255ba06c1189c8dc0ca409494314547c33ecb61f724582fcb0f69afc283</originalsourceid><addsrcrecordid>eNp1kUtLxDAUhYMoPkZ_gBsJuHHTMa82iTsZfIEioq5LmiYzGdpmTNrF_HtTZlRQXN3A-c65ufcCcIrRFGPOLzHNCctFTijGgnBEdsAhZpxnSHK0m95Jz0bgABzFuEQIcU7zfXBAORNSIH4I6pdBNa5fQ29h46yBceGHpoaVgf3CwFVwrQpJHXrtWwOtD7B20ahostbXzq5dNx_JoFZr2AenmghdB59er-DMt63p-mQ_Bns2CeZkWyfg_fbmbXafPT7fPcyuHzNNCeozSRnGmuR5pVCh00hSi1ojrRiSTDKKWc64ptToqsCWj6MTqytkC6msJoJOwMUmdxX8x2BiX7YuatM0qjN-iCURDAuBUVEk9PwXuvRD6NLvRkpgKoXkicIbSgcfYzC23C6kxKgcT1D-OUHynG2Th6o19bfja-cJmG6AqObmp-3_iZ8NM40G</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2848139897</pqid></control><display><type>article</type><title>Quality of life should be the primary outcome for disease-modifying therapy trials in MS: Commentary</title><source>MEDLINE</source><source>SAGE Journals Online</source><creator>Giovannoni, Gavin</creator><creatorcontrib>Giovannoni, Gavin</creatorcontrib><identifier>ISSN: 1352-4585</identifier><identifier>EISSN: 1477-0970</identifier><identifier>DOI: 10.1177/13524585231182702</identifier><identifier>PMID: 37489807</identifier><language>eng</language><publisher>London, England: SAGE Publications</publisher><subject>Humans ; Immunosuppressive Agents ; Multiple Sclerosis - drug therapy ; Multiple Sclerosis, Relapsing-Remitting - drug therapy ; Quality of Life</subject><ispartof>Multiple sclerosis, 2023-08, Vol.29 (9), p.1068-1069</ispartof><rights>The Author(s), 2023</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c320t-93411c255ba06c1189c8dc0ca409494314547c33ecb61f724582fcb0f69afc283</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://journals.sagepub.com/doi/pdf/10.1177/13524585231182702$$EPDF$$P50$$Gsage$$H</linktopdf><linktohtml>$$Uhttps://journals.sagepub.com/doi/10.1177/13524585231182702$$EHTML$$P50$$Gsage$$H</linktohtml><link.rule.ids>314,780,784,21818,27923,27924,43620,43621</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37489807$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Giovannoni, Gavin</creatorcontrib><title>Quality of life should be the primary outcome for disease-modifying therapy trials in MS: Commentary</title><title>Multiple sclerosis</title><addtitle>Mult Scler</addtitle><subject>Humans</subject><subject>Immunosuppressive Agents</subject><subject>Multiple Sclerosis - drug therapy</subject><subject>Multiple Sclerosis, Relapsing-Remitting - drug therapy</subject><subject>Quality of Life</subject><issn>1352-4585</issn><issn>1477-0970</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kUtLxDAUhYMoPkZ_gBsJuHHTMa82iTsZfIEioq5LmiYzGdpmTNrF_HtTZlRQXN3A-c65ufcCcIrRFGPOLzHNCctFTijGgnBEdsAhZpxnSHK0m95Jz0bgABzFuEQIcU7zfXBAORNSIH4I6pdBNa5fQ29h46yBceGHpoaVgf3CwFVwrQpJHXrtWwOtD7B20ahostbXzq5dNx_JoFZr2AenmghdB59er-DMt63p-mQ_Bns2CeZkWyfg_fbmbXafPT7fPcyuHzNNCeozSRnGmuR5pVCh00hSi1ojrRiSTDKKWc64ptToqsCWj6MTqytkC6msJoJOwMUmdxX8x2BiX7YuatM0qjN-iCURDAuBUVEk9PwXuvRD6NLvRkpgKoXkicIbSgcfYzC23C6kxKgcT1D-OUHynG2Th6o19bfja-cJmG6AqObmp-3_iZ8NM40G</recordid><startdate>202308</startdate><enddate>202308</enddate><creator>Giovannoni, Gavin</creator><general>SAGE Publications</general><general>Sage Publications Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TK</scope><scope>7U9</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope></search><sort><creationdate>202308</creationdate><title>Quality of life should be the primary outcome for disease-modifying therapy trials in MS: Commentary</title><author>Giovannoni, Gavin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c320t-93411c255ba06c1189c8dc0ca409494314547c33ecb61f724582fcb0f69afc283</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Humans</topic><topic>Immunosuppressive Agents</topic><topic>Multiple Sclerosis - drug therapy</topic><topic>Multiple Sclerosis, Relapsing-Remitting - drug therapy</topic><topic>Quality of Life</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Giovannoni, Gavin</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Multiple sclerosis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Giovannoni, Gavin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Quality of life should be the primary outcome for disease-modifying therapy trials in MS: Commentary</atitle><jtitle>Multiple sclerosis</jtitle><addtitle>Mult Scler</addtitle><date>2023-08</date><risdate>2023</risdate><volume>29</volume><issue>9</issue><spage>1068</spage><epage>1069</epage><pages>1068-1069</pages><issn>1352-4585</issn><eissn>1477-0970</eissn><cop>London, England</cop><pub>SAGE Publications</pub><pmid>37489807</pmid><doi>10.1177/13524585231182702</doi><tpages>2</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1352-4585
ispartof Multiple sclerosis, 2023-08, Vol.29 (9), p.1068-1069
issn 1352-4585
1477-0970
language eng
recordid cdi_proquest_miscellaneous_2841881066
source MEDLINE; SAGE Journals Online
subjects Humans
Immunosuppressive Agents
Multiple Sclerosis - drug therapy
Multiple Sclerosis, Relapsing-Remitting - drug therapy
Quality of Life
title Quality of life should be the primary outcome for disease-modifying therapy trials in MS: Commentary
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-10T23%3A05%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Quality%20of%20life%20should%20be%20the%20primary%20outcome%20for%20disease-modifying%20therapy%20trials%20in%20MS:%20Commentary&rft.jtitle=Multiple%20sclerosis&rft.au=Giovannoni,%20Gavin&rft.date=2023-08&rft.volume=29&rft.issue=9&rft.spage=1068&rft.epage=1069&rft.pages=1068-1069&rft.issn=1352-4585&rft.eissn=1477-0970&rft_id=info:doi/10.1177/13524585231182702&rft_dat=%3Cproquest_cross%3E2848139897%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2848139897&rft_id=info:pmid/37489807&rft_sage_id=10.1177_13524585231182702&rfr_iscdi=true